CLEARPOINT NEURO INC (CLPT)
Health Care · Medical Devices - Neurosurgical · NASDAQ
ClearPoint Neuro provides advanced image-guided navigation and delivery platforms to enable precise, minimally invasive neurosurgical procedures.
What CLEARPOINT NEURO INC does
ClearPoint Neuro is a medical device company that provides navigational platforms and software-controlled delivery systems for neurosurgical procedures. Its technology is designed to enable minimally invasive, real-time image-guided therapy for conditions such as epilepsy, brain tumors, and movement disorders. The company also offers clinical services and support through its ClearPoint Advanced Laboratories.
Themes: neurosurgery, image-guided surgery, neurological disorders, minimally invasive surgery, brain intervention, neuro-navigation technology
Fundamentals
- Price$15.17 as of 2026-08-24 close
- Market cap$463M as of 2026-08-24
- 1-year return+41.8% 2025-08-22 close $10.70 → 2026-08-24 close $15.17
- P/En/a negative earnings
- Net margin-71.6% as of 2026-08-24
- Gross margin+62.3% as of 2026-08-24
- ROE-141.0% as of 2026-08-24
- Debt / equity2.63 as of 2026-08-24
- Revenue growth (YoY)+26.0% as of 2026-08-24
- Revenue CAGR (3y)+21.6% SEC XBRL
- Beta2.00 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How CLPT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CLEARPOINT NEURO INC looks technically
CLEARPOINT NEURO INC (CLPT) is trading 14.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 22 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 48.9% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 14.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $15.76 | $15.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.50 | $13.50 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 12.27. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 22 trading days ago — a "golden cross", a bullish long-term signal | 22 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 14.0% above | +14.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($12.27 to $16.08) — its "stochastic" reading is 82 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 81.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $30.10 | $30.10 |
|---|---|---|
| From the 52-week high | it is 48.9% below its 52-week high (its highest price of the past year) | -48.9% |
| Above the 52-week low | it is 86.1% above its 52-week low (its lowest price of the past year) | +86.1% |
| Below the 52-week high | it is 48.9% below its highest point of the past year | 48.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 38 trading days ago | 38 sessions |
| All-time high | its highest closing price on record is $200.00 (set on 2012-07-03) | $200.00 |
| Given back of the 52-week move | over the past year its closes ranged ($8.66 to $29.60), and it has recovered roughly a third of its fall from last year’s high — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $21.60 to $22.27. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.1% |
| From the all-time high | it is 92.3% below its all-time high | -92.3% |
| Nearest price level | it is trading 1.0% below a resistance level at $15.54 — a price it turned at twice since 2025-04-25, most recently on 2026-08-03. Since 2024-08-21 it has 14 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $1.33 (set on 2018-12-26) | $1.33 |
| Above the all-time low | it is 1057.1% above its all-time low | +1,057% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 82% of it) | 18th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8197 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8197 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.12 and $16.33 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.12 – $14.72 – $16.33 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges above its 200-day average price (14.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 4.6% above the previous close 10 sessions ago and has not traded back through the level it left behind at 13.39 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.6% |
| Gap filled | a 15.3% gap down opened on 2026-08-04 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.5 percentage points (the stock lost 0.1% while the market gained 2.3%) | -2.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 28.4 percentage points (the stock gained 31.5% while the market gained 3.1%) | +28.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 2.3 percentage points (the stock gained 8.8% while the market gained 11.1%) | -2.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 29.8 percentage points (the stock gained 50.3% while the market gained 20.5%) | +29.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $13.30 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +15.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $14.26 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +8.0% |
Price levels it has turned at before
CLPT last closed at $15.39 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.54 | Resistance | 1.0% above the last close | turned there twice · 2025-04-25 to 2026-08-03 |
| $15.21 | Support | 1.1% below the last close | turned there three times · 2025-12-22 to 2026-06-04 |
| $14.79 | Support | 3.9% below the last close | turned there three times · 2025-05-12 to 2025-11-25 |
| $16.47 | Resistance | 7.0% above the last close | turned there four times · 2025-01-06 to 2026-01-23 |
| $14.19 | Support | 7.8% below the last close | turned there five times · 2024-10-18 to 2025-06-09 |
| $19.04 | Resistance | 23.7% above the last close | turned there three times · 2025-01-21 to 2025-02-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $12.27.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $20.97 and $26.35 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $12.27.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$25.67 range $22.00 – $30.00; median $25.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CLPT
- Consensus EPS estimate-$0.3233 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Continued operating losses and need for additional capital to fund operations.","Risks associated with the regulatory approval process for new products and indications.","Dependence on a limited number of neurosurgical centers for significant portions of revenue."]
What changed in the latest 10-Q
AI-assisted comparison of CLPT's 10-Q filed 2026-05-13 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- 2025 10-K reference added (newer filing references 'Annual Report on Form 10-K for the year ended December 31, 2025')
- IRRAS acquisition mentioned as expanding portfolio into neurocritical care in 2025
- IRRA flow system added to portfolio of medical devices for intracranial fluid management
- ClearPoint Navigation Software Version 3.0 released in 2025 for end-to-end operating room procedures
- Preclinical development services described as including 'protocol consultation and solutions for preclinical study design and execution' with 'core competency of in vivo biology services'
- FDA marketing authorization for SmartFlow cannula for gene therapy delivery mentioned for aromatic L-amino acid decarboxylase deficiency
- Business described as 'two integrated components' explicitly stated upfront
- Neurocritical care focus with treatment mentions for intracerebral hemorrhage and intraventricular hemorrhage
- Removed:
- Accumulated losses figure of $209.1 million removed
- Statement about financing through 'sale of equity securities and the issuance of notes payable' removed
- Statement about 'significant losses since our inception in 1998' removed
- Detailed paragraph on consulting services for improving 'outcome predictability and optimizing preclinical and clinical workflows' removed
- Reference to 'benchtop testing, preclinical studies, clinical trial support, regulatory consultation' removed
- Language about 'translation from the preclinical to the clinical setting' removed
- Product revenue figures ($5.4 million and $16.6 million for three and nine months ended September 30, 2025) removed
- Reworded:
- Description changed from 'innovative platforms for performing minimally invasive surgical procedures' to 'integrated systems used in minimally invasive neurosurgical procedures'
- Changed from 'capabilities for enabling neurosurgery interventions' to 'foundational capabilities for enabling MRI-guided interventions'
- SmartFrame OR Stereotactic System status changed from 'commenced limited market release' to 'introduced to the market'
- ClearPoint Prism description changed: removed 'for which we have exclusive global rights to commercialize, received 510(k) clearance through our Swedish partner, CLS. The Prism laser represents the first therapy product we have commercialized' and replaced with shorter description noting 'developed and is manufactured for us by CLS. We have exclusive global rights to commercialize the system for neuro applications'
- Changed 'funding through capital markets' to 'our ability to access capital markets' in macroeconomic section
- 2024 Form 10-K reference changed to 'Annual Report on Form 10-K for the year ended December 31, 2025'
- Notes:
- The newer filing is a Q1 10-Q (for period ending March 31, 2026) while the older filing is a Q3 10-Q (for period ending September 30, 2025), so some changes may reflect different reporting periods and updated information
- Revenue figures were removed entirely from the newer excerpt shown, making direct comparison incomplete for that section
- The newer filing excerpt ends mid-sentence at 'In September 2022, the ClearPoint Prism Neuro Laser Therapy', so the full context of changes to this section may not be fully captured
Risk Factors
- Added:
- Added IRRAS® and IRRAFLOW® to the list of trademarks in the newer filing (2026-05-13)
- Added fuller forward-looking statements language including 'statements, other than statements of historical fact' in the newer filing
- Added reference to 'Part II, Item 1.A of this Quarterly Report' in forward-looking statements caveat in newer filing
- Added reference to 2025 Form 10-K filed March 17, 2026 in newer filing (vs. 2024 Form 10-K filed February 26, 2025 in older filing)
- Added 'Goodwill' and 'Intangible assets, net' line items to the balance sheet in newer filing (March 31, 2026)
- Removed:
- Removed 'SmartFrame OR®' trademark from older filing (still present in newer filing - no removal)
- Removed 'and short-term investments' language from forward-looking statements in newer filing
- Removed 'Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report' language in newer filing
- Removed separate nine-month consolidated statements of operations (present in older filing only)
- Reworded:
- Changed from 'This Quarterly Report contains' to 'This Quarterly Report on Form 10-Q contains' in forward-looking statements header
- Changed forward-looking statements opening from 'All statements, other than statements of historical fact, in this Quarterly Report' structure with fuller descriptive text in newer filing
- Expanded explanation of forward-looking statement identification with additional context in newer filing regarding reasonableness basis
- Changed reference from '2024 Form 10-K' to '2025 Form 10-K' with updated SEC filing date from February 26, 2025 to March 17, 2026
- Added reference to statements based on 'information available to us as of the date of this Quarterly Report' with caveat about limited/incomplete information in newer filing
- Changed 'short-term investments' reference removed from adequacy language in newer filing
- Notes:
- The older filing provided is truncated and does not include complete financial statements or stockholders' equity section
- Balance sheet line items differ between filings due to different reporting periods (Q1 2026 vs Q3 2025) and may include acquisition-related changes
- Statement of operations structure differs between filings (three months only in newer vs. three and nine months in older)
- Stockholders' equity statement is truncated in both filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($2M) — 2 selling insiders
- Last 180 days0 buys · 6 sells ($2M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CLPT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CLPT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 2,871,241
- Reported value $26,128,294
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CLPT had 3,894,322 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CLPT had 12.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.51 days to cover at the same settlement.
- Reported short interest (shares) 3,894,322
- Short interest (% of shares outstanding) 12.8%
- Prior settlement (shares) 3,695,062
- Reported change 5.39%
- Days to cover (reported) 7.51
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Stryker (SYK)
- Brainlab AG
- Renishaw plc
- Integra LifeSciences (IART)
- Boston Scientific (BSX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CLPT vs…
CLEARPOINT NEURO INC is found in…
Frequently asked questions
What does CLEARPOINT NEURO INC (CLPT) do?
ClearPoint Neuro is a medical device company that provides navigational platforms and software-controlled delivery systems for neurosurgical procedures. Its technology is designed to enable minimally invasive, real-time image-guided therapy for conditions such as epilepsy, brain tumors, and movement disorders. The company also offers clinical services and support through its ClearPoint Advanced Laboratories.
What sector is CLEARPOINT NEURO INC (CLPT) in?
CLEARPOINT NEURO INC (CLPT) is classified in the Health Care sector. Its industry is Medical Devices - Neurosurgical. It trades on NASDAQ.
Who are CLEARPOINT NEURO INC's (CLPT) competitors?
Notable peers of CLEARPOINT NEURO INC (CLPT) include Medtronic, Stryker, Brainlab AG, Renishaw plc and Integra LifeSciences. This peer set is informational only — not financial advice.
Is CLEARPOINT NEURO INC (CLPT) overbought or oversold right now?
CLEARPOINT NEURO INC (CLPT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CLPT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.